ESR1 and breast carcinoma: Given the heterogeneous property, this cell line is widely used as a model to study the endocrine therapy/drug resistance development process in ER+/luminal A breast cancer by identifying and understanding the molecular profile of the possible drug-resistant subclones (or subpopulations) 12-14.